Pay in 4 interest-free payments of $6.35 Learn more
Ships within 48 hours · Estimated delivery Aug 12 - Aug 17
Ped Rev & Commns .1994
Gradual dose titration prevents most severe GI effects
Approved as a once-weekly GLP-1 receptor agonist for chronic weight management in adults with obesity or overweight-related health conditions, Wegovy entered the India Semaglutide market ahead of its patent expiry to counter rising competition from Eli Lillys Mounjaro
Healthcare providers should stay informed of evolving research in this area and consider how adjunctive metabolic therapies might benefit their patients struggling with obesity and metabolic syndrome
2022;106(9):e40412
US$ 27.98
US$ 22.09
US$ 27.82
US$ 25.14
US$ 28.89
